Legend Biotech Corporation (LEGN)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). The investigation concerns whether Legend and certain of its officers and/or directors have violated federal securities laws.

 

On September 21, 2020, Legend issued a press release announcing that its Chief Executive Officer, Dr. Fangliang Zhang, has been placed under residential surveillance by Chinese law enforcement authorities.  In addition, Legend announced that the Chinese Customs Anti-Smuggling Department has inspected certain business facilities of GenScript Biotech Corporation, Legend’s parent and majority shareholder, in connection with suspected violations of import and export regulations under Chinese law.  On this news, Legend’s stock price fell sharply during intraday trading on September 21, 2020.

      

If you are aware of any facts relating to this investigation, or purchased Legend shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.